What is the intrinsic value of KROS?
As of 2025-10-17, the Intrinsic Value of Keros Therapeutics Inc (KROS) is
2.31 USD. This KROS valuation is based on the model Peter Lynch Fair Value.
With the current market price of 13.74 USD, the upside of Keros Therapeutics Inc is
-83.18%.
Is KROS undervalued or overvalued?
Based on its market price of 13.74 USD and our intrinsic valuation, Keros Therapeutics Inc (KROS) is overvalued by 83.18%.
KROS Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(906.65) - (82.25) |
(156.81) |
-1241.2% |
| DCF (Growth 10y) |
(84.34) - (836.63) |
(152.81) |
-1212.2% |
| DCF (EBITDA 5y) |
(52.12) - (77.80) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(59.73) - (89.45) |
(1,234.50) |
-123450.0% |
| Fair Value |
2.31 - 2.31 |
2.31 |
-83.18% |
| P/E |
12.17 - 15.83 |
14.28 |
3.9% |
| EV/EBITDA |
17.61 - 19.14 |
18.13 |
32.0% |
| EPV |
(23.00) - (37.69) |
(30.35) |
-320.9% |
| DDM - Stable |
3.93 - 18.98 |
11.45 |
-16.6% |
| DDM - Multi |
(32.33) - (125.96) |
(52.00) |
-478.4% |
KROS Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
558.12 |
| Beta |
1.16 |
| Outstanding shares (mil) |
40.62 |
| Enterprise Value (mil) |
-132.10 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.21% |
| Cost of Debt |
5.00% |
| WACC |
6.44% |